JP2006512291A - 男性勃起障害の治療方法 - Google Patents

男性勃起障害の治療方法 Download PDF

Info

Publication number
JP2006512291A
JP2006512291A JP2004534659A JP2004534659A JP2006512291A JP 2006512291 A JP2006512291 A JP 2006512291A JP 2004534659 A JP2004534659 A JP 2004534659A JP 2004534659 A JP2004534659 A JP 2004534659A JP 2006512291 A JP2006512291 A JP 2006512291A
Authority
JP
Japan
Prior art keywords
composition
prostaglandin
group
aliphatic
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004534659A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイムズ エル. イーガー、
ナディア ブユクティムキン、
サーベット ブユクティムキン、
Original Assignee
ネックスメド ホールディングス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/236,485 external-priority patent/US7105571B2/en
Application filed by ネックスメド ホールディングス インコーポレイテッド filed Critical ネックスメド ホールディングス インコーポレイテッド
Publication of JP2006512291A publication Critical patent/JP2006512291A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2004534659A 2002-09-06 2003-09-05 男性勃起障害の治療方法 Pending JP2006512291A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/236,485 US7105571B2 (en) 2000-01-10 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction
US48327803P 2003-06-27 2003-06-27
PCT/US2003/027885 WO2004022064A1 (fr) 2002-09-06 2003-09-05 Procedes de traitement des troubles de l'erection chez l'homme

Publications (1)

Publication Number Publication Date
JP2006512291A true JP2006512291A (ja) 2006-04-13

Family

ID=31980977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004534659A Pending JP2006512291A (ja) 2002-09-06 2003-09-05 男性勃起障害の治療方法

Country Status (10)

Country Link
EP (1) EP1534297A1 (fr)
JP (1) JP2006512291A (fr)
KR (1) KR20050057245A (fr)
CN (1) CN1674912A (fr)
AU (1) AU2003273291A1 (fr)
CA (1) CA2493723A1 (fr)
EA (1) EA200500452A1 (fr)
IL (1) IL166273A0 (fr)
NO (1) NO20050658L (fr)
WO (1) WO2004022064A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
JP2006520788A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物による血管形成促進および方法
MXPA05010069A (es) * 2003-03-21 2005-11-23 Nexmed Holdings Inc Composiciones de prostaglandina para el tratamiento de la disfuncion erectil.
EP3266458A1 (fr) 2016-07-05 2018-01-10 Fagron B.V. Procédé et composition et kit pour traiter un dysfonctionnement érectile

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
WO2003070281A1 (fr) * 2002-02-15 2003-08-28 Nexmed (Holdings), Inc. Composition de prostaglandine pour le traitement des troubles de l'erection

Also Published As

Publication number Publication date
CN1674912A (zh) 2005-09-28
EP1534297A1 (fr) 2005-06-01
NO20050658L (no) 2005-04-01
EA200500452A1 (ru) 2005-10-27
AU2003273291A1 (en) 2004-03-29
CA2493723A1 (fr) 2004-03-18
WO2004022064A1 (fr) 2004-03-18
IL166273A0 (en) 2006-01-15
KR20050057245A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
US6323241B1 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
EP1423147B1 (fr) Compositions de prostaglandine et procedes de traitement de troubles de l'erection chez l'homme
AU2002323650A1 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
US8632813B2 (en) Prostaglandin compositions and methods for the treatment of vasospasm
US20030220292A1 (en) Treatment of erectile dysfunction
US20040110843A1 (en) Methods of treatment of male erectile dysfunction
JP2006512291A (ja) 男性勃起障害の治療方法
KR20050119136A (ko) 프로스타글란딘 조성물에 의한 혈관형성 촉진 및 방법
TWI324930B (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction